Clinical trial
S0312, Gemcitabine and Capecitabine in Treating Patients With Advanced Renal…
NCT00058318 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00058318 |
|---|---|
| Title | S0312, Gemcitabine and Capecitabine in Treating Patients With Advanced Renal Cell (Kidney) Cancer |
| Official title | A Phase II Study of IV Gemcitabine and Oral Capecitabine in Patients With Advanced Renal Cell Cancer |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Drug |
| Interventions | capecitabine, gemcitabine hydrochloride |
| Enrollment | 43 |
| Start date | Dec 1, 2004 |
| Primary completion | May 1, 2007 |
| Completion | Nov 1, 2008 |
| First posted | Apr 9, 2003 |
| Last update posted | Nov 2, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: